Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study

. 2022 Apr 01 ; 106 (4) : 842-852.

Jazyk angličtina Země Spojené státy americké Médium print

Typ dokumentu klinická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid34999659
Odkazy

PubMed 34999659
PubMed Central PMC8942601
DOI 10.1097/tp.0000000000004044
PII: 00007890-202204000-00027
Knihovny.cz E-zdroje

BACKGROUND: Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has been recently shown to be impaired in kidney transplant recipients (KTRs), but the underlying factors affecting vaccine effectiveness need to be further elucidated. METHODS: In this prospective cohort study, antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%) in 736 KTRs, who were previously either naive or infected with SARS-CoV-2 and vaccinated before or after transplantation. Cellular response was analyzed in a subset of patients using an interferon gamma release assay (cutoff 0.15 IU/mL, sensitivity 92%, and specificity 100%). RESULTS: Seroconversion was significantly more impaired in SARS-CoV-2-naive KTRs than in those previously infected (40.1% versus 97.1%; P < 0.001). Mycophenolate use (odds ratio, 0.15; 95% confidence interval, 0.09-0.24; P < 0.001) and depleting therapy in the past year (odds ratio, 0.19; 95% confidence interval, 0.05-0.8; P = 0.023) were found to be among independent factors associated with impaired humoral response. Similarly, the interferon gamma release assay tested in 50 KTRs (cutoff 0.15 IU/mL, sensitivity 92%, specificity 100%) showed that specific T-cell responses against spike protein epitopes are impaired in SARS-CoV-2-naive KTRs, as compared to previously infected KTRs (9.4% versus 90%, P < 0.001). All 35 KTRs vaccinated on the waiting list before transplantation exhibited sustained seroconversion persisting after transplantation. CONCLUSIONS: Survivors of coronavirus disease 2019 and those vaccinated while on the waiting list exhibited a marked immune response to mRNA vaccines, contrary to poor response in naive KTRs vaccinated after transplantation (NCT04832841).

Zobrazit více v PubMed

Akalin E, Azzi Y, Bartash R, et al. . Covid-19 and kidney transplantation. N Engl J Med. 2020;382:2475–2477. PubMed PMC

Haas EJ, Angulo FJ, McLaughlin JM, et al. . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–1829. PubMed PMC

Amit S, Regev-Yochay G, Afek A, et al. . Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–877. PubMed PMC

Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. PubMed PMC

Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. PubMed PMC

Walsh EE, Frenck RW, Jr, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. PubMed PMC

Sattler A, Schrezenmeier E, Weber UA, et al. . Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131:150175. PubMed PMC

Devresse A, Saad Albichr I, Georgery H, et al. . T-cell and antibody response after 2 doses of the BNT162b2 vaccine in a belgian cohort of kidney transplant recipients. Transplantation. 2021;105:e142–e143. PubMed PMC

Rozen-Zvi B, Yahav D, Agur T, et al. . Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27:1173.e1–1173.e4. PubMed PMC

Magicova M, Fialova M, Zahradka I, et al. . Humoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipients. Am J Transplant. 2021;21:3926–3935. PubMed PMC

Bertrand D, Hamzaoui M, Lemée V, et al. . Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147–2152. PubMed PMC

Cucchiari D, Egri N, Bodro M, et al. . Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21:2727–2739. PubMed PMC

Georgery H, Devresse A, Yombi J-C, et al. . Disappointing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients. Transplantation. 2021;105:e283–e284. PubMed PMC

Anichini G, Terrosi C, Gandolfo C, et al. . SARS-CoV-2 antibody response in persons with past natural infection. N Engl J Med. 2021;385:90–92. PubMed PMC

Havlin J, Svorcova M, Dvorackova E, et al. . Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021;40:754–758. PubMed PMC

Bonelli F, Sarasini A, Zierold C, et al. . Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020;58:e01224–20. PubMed PMC

The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390–1400. PubMed PMC

National Institutes of Health. Clinical spectrum of SARS-CoV-2 infection. COVID-19 Treatment Guidelines Panel. 2021. Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed September 25, 2021. PubMed

Simon B, Rubey H, Treipl A, et al. . Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant. 2021;36:1709–1716. PubMed PMC

Grupper A, Sharon N, Finn T, et al. . Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16:1037–1042. PubMed PMC

Danthu C, Hantz S, Dahlem A, et al. . Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32:2153–2158. PubMed PMC

Baluch A, Humar A, Eurich D, et al. . Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13:1026–1033. PubMed

Egli A, Humar A, Widmer LA, et al. . Effect of immunosuppression on T-helper 2 and B-cell responses to influenza vaccination. J Infect Dis. 2015;212:137–146. PubMed

Kamar N, Abravanel F, Marion O, et al. . Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662. PubMed PMC

Stumpf J, Tonnus W, Paliege A, et al. . Cellular and humoral immune responses after 3 doses of BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant. Transplantation. 2021;105:e267–e269. PubMed PMC

Alejo JL, Mitchell J, Chiang TPY, et al. . Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2021;105:e280–e281. PubMed PMC

American Society of Transplantation. Updated Joint AST/ASTS/ISHLT Statement about vaccine efficacy in organ transplant recipients. 2021. Available at https://www.myast.org/statement-covid-19-vaccination-solid-organ-transplant-recipients. Accessed July 14, 2021.

Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. . Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325:1467–1469. PubMed PMC

Stamatatos L, Czartoski J, Wan YH, et al. . mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413–1418. PubMed PMC

Reynolds CJ, Pade C, Gibbons JM, et al. . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418–1423. PubMed PMC

Boyarsky BJ, Barbur I, Chiang TP, et al. . SARS-CoV-2 messenger RNA vaccine immunogenicity in solid organ transplant recipients with prior COVID-19. Transplantation. 2021;105:e270–e271. PubMed PMC

Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. . Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27:1525–1529. PubMed PMC

Boyarsky BJ, Werbel WA, Avery RK, et al. . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204–2206. PubMed PMC

Steensels D, Pierlet N, Penders J, et al. . Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326:1533–1535. PubMed PMC

Viklicky O, Fronek J, Trunecka P, et al. . Organ transplantation in the czech republic. Transplantation. 2017;101:2259–2261. PubMed

Burack D, Pereira MR, Tsapepas DS, et al. . Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. Am J Transplant. 2021;21:2254–2261. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04832841

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...